Jefferies is out with its report on Charles River Laboratories CRL as CRL is set to report guidance on December, 14.
In a report to clients, Jefferies notes, "We have picked up some minor indications of improvement in toxicology. Authorizations are higher now than 1 year ago...more so on volume than value. Our position on early development has been negative for many quarters. We haven't been burned badly, yet we're plenty cautious about adding another call on a headfake to the many already made by the sell-side. Moreover, with the sequential decline in PCS revenue during 2010, sequential improvement in 2011 will be required just to climb back to flat.
Jefferies has a Hold rating and increases its price target from $33 to $35 on CRL.
CRL closed yesterday at $34.82.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsCharles River LaboratoriesHealth CareJefferiesLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in